These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20595906)

  • 1. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.
    Taylor SA; Lee GA; Pao VY; Anthonypillai J; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):361-4. PubMed ID: 20595906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.
    Lee GA; Lo JC; Aweeka F; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    Clin Infect Dis; 2006 Sep; 43(5):658-60. PubMed ID: 16886163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
    Lee GA; Rao M; Mulligan K; Lo JC; Aweeka F; Schwarz JM; Schambelan M; Grunfeld C
    AIDS; 2007 Oct; 21(16):2183-90. PubMed ID: 18090045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
    Pao VY; Lee GA; Taylor S; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2010 Jan; 24(2):265-70. PubMed ID: 19890203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
    Noor MA; Flint OP; Maa JF; Parker RA
    AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
    Dubé MP; Shen C; Greenwald M; Mather KJ
    Clin Infect Dis; 2008 Aug; 47(4):567-74. PubMed ID: 18636958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
    Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
    AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
    Yan Q; Hruz PW
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):398-403. PubMed ID: 16280693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.
    Lee GA; Schwarz JM; Patzek S; Kim S; Dyachenko A; Wen M; Mulligan K; Schambelan M; Grunfeld C
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):246-8. PubMed ID: 19680131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
    Busti AJ; Bedimo R; Margolis DM; Hardin DS
    J Investig Med; 2008 Feb; 56(2):539-44. PubMed ID: 18317438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
    Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
    Randell P; Jackson A; Milinkovic A; Boffito M; Moyle G
    Antivir Ther; 2017; 22(2):145-151. PubMed ID: 27708251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
    Noor MA; Seneviratne T; Aweeka FT; Lo JC; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2002 Mar; 16(5):F1-8. PubMed ID: 11964551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
    Hruz PW; Yan Q; Tsai L; Koster J; Xu L; Cihlar T; Callebaut C
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1377-82. PubMed ID: 21245443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
    d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
    Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model.
    Hruz PW; Yan Q
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):624-5. PubMed ID: 17133213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.